Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 5Breast Neoplasms 5Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Lymphoma 4Leukemia, Myeloid, Acute 4Hodgkin Disease 4Hematologic Neoplasms 4Waldenstrom Macroglobulinemia 3Myelodysplastic Syndromes 3Mycosis Fungoides 3Lymphoma, T-Cell 3Lymphoma, Mantle-Cell 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Sezary Syndrome 2Sarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Parathyroid Neoplasms 2Otorhinolaryngologic Neoplasms 2Osteosarcoma 2Neoplasms 2Mixed Tumor, Mesodermal 2Mesothelioma, Cystic 2

Interventions

Paclitaxel 2Kidney Transplantation 2Cyclophosphamide 2Azacitidine 2veliparib 1trifluridine tipiracil drug combination 1trebananib 1safinamide 1sacubitril and valsartan sodium hydrate drug combination 1rubitecan 1ripretinib 1regorafenib 1pomalidomide 1pevonedistat 1osimertinib 1mirabegron 1glucarpidase 1gamma-Glutamyl Hydrolase 1dabrafenib 1copanlisib 1belinostat 1belantamab mafodotin 1Whole-Body Irradiation 1Topotecan 1Taxes 1Sitagliptin Phosphate 1Rituximab 1Pharmacogenomic Testing 1Oxaliplatin 1Methotrexate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Renal Insufficiency × belinostat × Clear all
NCT02679131 2019-11-20

To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.

Acrotech Biopharma Inc.

Phase 1 Terminated
18 enrolled
Other hematologic neoplasm

Recurrence, Hematologic Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡